CFTR and cystic fibrosis: There are currently four FDA-approved drugs that are used to treat CF: The type I correctors lumacaftor (VX-809) and tezacaftor (VX-661) stabilize mutant CFTR variants (predominantly the most common ΔF508 mutation) reducing premature protein degradation and improving surface presentation of the mature channel (Van Goor et al., 2011; Fiedorczuk and Chen, 2022b).